Please provide your email address to receive an email when new articles are posted on . Overall, 34% of transgender and gender-diverse adults reported breakthrough bleeding while on testosterone.
An expert explains the unique dosing considerations for emicizumab compared to factor VIII in hemophilia A, covering prophylaxis and breakthrough bleeding scenarios. This is a video synopsis/summary ...
Over one-third of hemophilia patients experience bleeding episodes and joint damage despite prophylactic therapies, indicating a need for more effective treatments. Data from the Adelphi Hemophilia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback